Linked Life Data

3531955

Source:http://linkedlifedata.com/resource/pubmed/id/3531955

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1986-11-7
pubmed:abstractText
We have tested by the computerized tube leukocyte adherence inhibition (LAI) assay, 319, 100 and 342 patients and controls for the presence of antitumor immunity to colorectal, breast and lung cancers. The assay was standardized and its sensitivity increased by using, as a challenging antigen, spent medium of human carcinoma cell lines and by the addition of prostaglandin E2 (PGE2). By large, the sensitivity of the assay (after the addition of PGE2) was inversely related to tumor burden, namely, it was 82.7, 78.9, and 88.6% as compared to 57.1, 33.3, and 29.6% for the early and late stages of colorectal, breast and lung cancers, respectively. Calculating the frequency of disease in the population studied and in comparison with known frequencies of the same in the general population, the positive and negative predicting values (PVpos, PVneg) were obtained. Our results demonstrate that the LAI assay cannot be applied for mass screening since its low PVpos would impair its effectiveness. However, its application to a population at high risk for developing a particular malignancy or as a second-line modality to more conventional screening methods would increase its cost-effectiveness and favor its applicability.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0030-2414
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
327-34
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Diagnostic value of the computerized tube leukocyte adherence inhibition (LAI) assay for human colorectal, breast and lung cancers.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't